Table 1. Baseline demographic and clinical features of the studied patients (n=128).
| Variable | Value |
|---|---|
| Age (yr) | 41.65±14.84 |
| Sex | |
| Female | 57 (44.5) |
| Male | 71 (55.5) |
| BMI (kg/m2)* | 24.27±3.98 |
| Duration of disease (mo) | 95.43±104.70 |
| PASI score† | 14.89±10.04 |
| ≤10 | 43 (38.4) |
| >10 | 69 (61.6) |
| Total medication period (d) | 324.45±338.38 |
| Cumulative dose (g) | 45.79±43.27 |
| Underlying diseases | |
| None | 98 (76.6) |
| Diabetes | 8 (6.3) |
| Hypertension | 14 (10.9) |
| Dyslipidemia | 9 (7.0) |
| Chronic hepatitis B infection | 3 (2.3) |
| Kidney disease | 1 (0.8) |
| Others‡ | 9 (7.0) |
Values are presented as mean±standard deviation or number (%). BMI: body mass index, PASI: psoriasis area and severity index. *Including only patients for whom BMI (n=57) was available. †Including only patients for whom PASI score (n=112) was available. ‡Angina, aortic dissection, autism, brain hemorrhage, stroke, thyroid disease.